The effects of zinc supplementation on metabolic profile and oxidative stress in overweight/obese patients with non-alcoholic fatty liver disease: A randomized, double-blind, placebo-controlled trial

被引:24
|
作者
Fathi, Mojdeh [1 ]
Alavinejad, Pezhman [2 ]
Haidari, Zahra [3 ]
Amani, Reza [1 ]
机构
[1] Isfahan Univ Med Sci, Food Secur Res Ctr, Sch Nutr & Food Sci, Dept Clin Nutr, Esfahan 8173948763, Iran
[2] Ahvaz Jundishapur Univ Med Sci, Ahvaz Imam Hosp, Alimentary Tract Res Ctr, Ahvaz, Iran
[3] Isfahan Univ Med Sci, Sch Hlth, Dept Biostat & Epidemiol, Esfahan, Iran
基金
美国国家科学基金会;
关键词
Zinc supplementation; Calorie- restriction diet; Non-alcoholic fatty liver; Insulin resistance; Oxidative stress; INSULIN-RESISTANCE; NONDIABETIC PATIENTS; GLYCEMIC CONTROL; LIPID PROFILES; OBESE; DEFICIENCY; STEATOHEPATITIS; PATHOGENESIS; HOMEOSTASIS; ADAPTATION;
D O I
10.1016/j.jtemb.2020.126635
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Background: Evidence indicates the positive effects of zinc on insulin resistance and oxidative stress in metabolic syndrome or diabetes. Non-alcoholic fatty liver disease (NAFLD) is the main hepatic manifestation of insulin resistance and metabolic syndrome. The present study is the first clinical trial that evaluated the effects of zinc supplementation on metabolic and oxidative stress status in overweight/obese patients with NAFLD undergoing calorie- restriction diet. Methods: Fifty six overweight/obese patients with confirmed mild to moderate NAFLD using ultrasonography were randomly allocated to receive 30 mg elemental zinc supplement (n = 29) or placebo (n = 27) along with weight loss diet for 12 weeks. Serum levels of zinc, homeostasis model of assessment-estimated insulin resistance (HOMA-IR), lipid profile, serum superoxide dismutasl (SOD1) and malondialdhyde (MDA) levels were assessed. Results: Serum levels of insulin, SOD1, MDA and HOMA-IR were improved in the treatment group (p < 0.05). Within group comparison showed significant reduction in serum FBS, HbA(1C), TC, LDL-c and TG in the treatment group. Conclusion: Zinc supplementation for three months improved insulin resistance and oxidative stress status in overweight/obese NAFLD patients with no beneficial effects on lipid profiles over weight loss diet.
引用
收藏
页数:6
相关论文
共 50 条
  • [11] The Effect of Curcumin Phytosome on the Treatment of Patients with Non-alcoholic Fatty Liver Disease: A Double-Blind, Randomized, Placebo-Controlled Trial
    Mirhafez, Seyed Reza
    Azimi-Nezhad, Mohsen
    Dehabeh, Maryam
    Hariri, Mitra
    Naderan, Ronika Danesh
    Movahedi, Ali
    Abdalla, Mohammed
    Sathyapalan, Thozhukat
    Sahebkar, Amirhossein
    PHARMACOLOGICAL PROPERTIES OF PLANT-DERIVED NATURAL PRODUCTS AND IMPLICATIONS FOR HUMAN HEALTH, 2021, 1308 : 25 - 35
  • [12] Effects of sumac (Rhus coriaria) on lipid profile, leptin and steatosis in patients with non-alcoholic fatty liver disease: A randomized double-blind placebo-controlled trial
    Ehsani, Simin
    Zolfaghari, Hamid
    Kazemi, Samira
    Shidfar, Farzad
    JOURNAL OF HERBAL MEDICINE, 2022, 31
  • [13] Effects of one-year supplementation with Phyllanthus niruri on fibrosis score and metabolic markers in patients with non-alcoholic fatty liver disease: A randomized, double-blind, placebo-controlled trial
    Abu Hassan, Muhammad Radzi
    Said, Rosaida Hj Md
    Zainuddin, Zalwani
    Omar, Haniza
    Ali, Siti Maisarah Md
    Aris, Siti Aishah
    Chan, Huan-Keat
    HELIYON, 2023, 9 (06)
  • [14] Synbiotic supplementation in lean patients with non-alcoholic fatty liver disease: a pilot, randomised, double-blind, placebo-controlled, clinical trial
    Mofidi, Fatemeh
    Poustchi, Hossein
    Yari, Zahra
    Nourinayyer, Babak
    Merat, Shahin
    Sharafkhah, Maryam
    Malekzadeh, Reza
    Hekmatdoost, Azita
    BRITISH JOURNAL OF NUTRITION, 2017, 117 (05) : 662 - 668
  • [15] Green cardamom supplementation improves serum irisin, glucose indices, and lipid profiles in overweight or obese non-alcoholic fatty liver disease patients: a double-blind randomized placebo-controlled clinical trial
    Daneshi-Maskooni, Milad
    Keshavarz, Seyed Ali
    Qorbani, Mostafa
    Mansouri, Siavash
    Alavian, Seyed Moayed
    Badri-Fariman, Mahtab
    Jazayeri-Tehrani, Seyed Ali
    Sotoudeh, Gity
    BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2019, 19 (1):
  • [16] Green cardamom supplementation improves serum irisin, glucose indices, and lipid profiles in overweight or obese non-alcoholic fatty liver disease patients: a double-blind randomized placebo-controlled clinical trial
    Milad Daneshi-Maskooni
    Seyed Ali Keshavarz
    Mostafa Qorbani
    Siavash Mansouri
    Seyed Moayed Alavian
    Mahtab Badri-Fariman
    Seyed Ali Jazayeri-Tehrani
    Gity Sotoudeh
    BMC Complementary and Alternative Medicine, 19
  • [17] Combined cranberry supplementation and weight loss diet in non-alcoholic fatty liver disease: a double-blind placebo-controlled randomized clinical trial
    Hormoznejad, Razie
    Shahi, Majid Mohammad
    Rahim, Fakher
    Helli, Bijan
    Alavinejad, Pezhman
    Sharhani, Asaad
    INTERNATIONAL JOURNAL OF FOOD SCIENCES AND NUTRITION, 2020, 71 (08) : 991 - 1000
  • [18] Green cardamom increases Sirtuin-1 and reduces inflammation in overweight or obese patients with non-alcoholic fatty liver disease: a double-blind randomized placebo-controlled clinical trial
    Daneshi-Maskooni, Milad
    Keshavarz, Seyed Ali
    Qorbani, Mostafa
    Mansouri, Siavash
    Alavian, Seyed Moayed
    Badri-Fariman, Mahtab
    Jazayeri-Tehrani, Seyed Ali
    Sotoudeh, Gity
    NUTRITION & METABOLISM, 2018, 15
  • [19] Green cardamom increases Sirtuin-1 and reduces inflammation in overweight or obese patients with non-alcoholic fatty liver disease: a double-blind randomized placebo-controlled clinical trial
    Milad Daneshi-Maskooni
    Seyed Ali Keshavarz
    Mostafa Qorbani
    Siavash Mansouri
    Seyed Moayed Alavian
    Mahtab Badri-Fariman
    Seyed Ali Jazayeri-Tehrani
    Gity Sotoudeh
    Nutrition & Metabolism, 15
  • [20] Inflammatory markers response to citrulline supplementation in patients with non-alcoholic fatty liver disease: a randomized, double blind, placebo-controlled, clinical trial
    Darabi, Zahra
    Darand, Mina
    Yari, Zahra
    Hedayati, Mehdi
    Faghihi, Amirhosein
    Agah, Shahram
    Hekmatdoost, Azita
    BMC RESEARCH NOTES, 2019, 12 (1) : V